MYC and neuroblastoma: As observed for Aurora-A, PROTAC technologies against BRD4 result in a stronger effect compared to BET inhibition; treatment with the MZ1 degrader induced a dose-dependent decrease in neuroblastoma cell viability, more than was observed after JQ1 administration, and reduced the protein levels of both N- and c-Myc [263].